Inventage Lab Presents mRNA-LNP Mass Production Platform Achievements at CRS

Inventage Lab, a drug delivery platform company, announced on July 6 that it will present its research results on mass production technology for mRNA-LNP (lipid nanoparticle) based on its proprietary IVL-GeneFluidic® platform in a poster session at the ‘CRS 2026 Annual Meeting & Exposition,’ an international conference in the drug delivery field.

CRS is a leading global academic conference representing the fields of drug delivery and controlled release, where global pharmaceutical and biotechnology companies and research institutions share the latest innovations in drug delivery technology and manufacturing. This year’s conference is being held in Lisbon, Portugal, from July 6 to 9, featuring the most up-to-date research in next-generation drug delivery technologies such as long-acting injectables (LAI), mRNA, nucleic acid drugs, and nanomedicines.

Recently, mRNA technology has rapidly expanded its applications beyond COVID-19 vaccines to cancer vaccines, rare disease therapeutics, and nucleic acid drugs. However, LNP (lipid nanoparticles), which safely deliver mRNA into the body, face challenges in maintaining consistent particle size and quality when scaling up manufacturing from laboratory to mass production. This has been considered one of the major technical hurdles for commercialization.

Inventage Lab explained that through this research, it demonstrated the capability to manufacture nucleic acid drugs based on LNP that maintain consistent quality from R&D to commercial production without scale-up issues, utilizing its unique microfluidic-based IVL-GeneFluidic® platform and the HANDYGENE™ series manufacturing system. In particular, by applying the ‘In-line Dilution’ technology, which reduces solvent concentration while simultaneously manufacturing LNPs, the company verified that it can stably maintain uniform particles regardless of production scale.

This achievement is significant in that it localizes LNP-based gene therapy and vaccine manufacturing systems, which have previously relied on foreign equipment such as PNI (Cytiva) and IJM Nanoscaler (KNAUER). The company stated that it succeeded in reducing dependence on foreign systems, independently securing commercialization tailored to domestic conditions, facilitating technology transfer, and establishing a stable supply chain.

According to the research results, various forms of RNA—including linear mRNA, self-amplifying mRNA, and circular mRNA—produced smaller and more uniform LNPs compared to conventional methods. The uniformity and particle size remained stable as production scaled up from small research batches to commercial levels. The production yield of the system improved up to 89%, and even with different production scales, animal tests confirmed that the same immune response was maintained, demonstrating preserved biological efficacy.

Notably, this research confirmed consistent manufacturing performance across the entire platform, from HANDYGENE Lab and HANDYGENE GMP to HANDYGENE Commercial, covering every stage from R&D to commercial production. This means that the manufacturing process established at the research stage can be applied in production without any process changes, leading to shorter development timelines, improved production efficiency, and reduced commercialization risks, according to the company.

The IVL-GeneFluidic® platform, developed by Inventage Lab, is a next-generation nucleic acid drug production platform characterized by its ability to precisely manufacture LNPs using microfluidic technology. The company expects that manufacturing conditions established during R&D can be directly extended to GMP and commercial production, enabling broad application not only for mRNA vaccines but also for next-generation nucleic acid drugs and various RNA-based therapeutics.

A representative from Inventage Lab stated, “This study demonstrates our core vision—‘One Process. One Platform. Any RNA, Any Scale’—on the global stage,” adding, “With the government’s strong support, we succeeded in developing a domestic mRNA-LNP manufacturing system that surpasses the limitations of existing global equipment.” He continued, “Having secured unrivaled marketability and competitiveness as a platform for vaccine and innovative therapeutic production, we will strengthen our domestic commercialization and technology transfer framework and further expand partnerships with global pharmaceutical companies.”

This research was supported by the Ministry of Trade, Industry and Energy’s Project for Advancing Vaccine Raw and Subsidiary Material Production Technology. Since being selected for the project in 2022, Inventage Lab has strengthened the technology competitiveness of the IVL-GeneFluidic® platform with ongoing government support and plans to build a next-generation domestic RNA and nucleic acid drug manufacturing ecosystem.

This content was produced with the assistance of AI translation services.